Skip to main content
Veterinary Medicines

Galliprant 100 mg - Tablet

Authorised
  • Grapiprant

Identifikazzjoni tal-prodott

Isem tal-mediċina:
Galliprant 100 mg - Tablet
Sustanza attiva:
Metodu ta’ amministrazzjoni:
  • Użu orali

Dettalji tal-prodott

Sustanza attiva / Qawwa:
  • Disponibbli biss fi English
    100.00
    milligram(s)
    /
    1.00
    Tablet
Forma farmaċewtika:
  • Pillola
Withdrawal period by route of administration:
  • Oral use
    • Dog
Kodiċi veterinarju anatomiku terapewtiku kimiku (ATCvet):
  • QM01AX
Status tal-awtorizzazzjoni:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Available in:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Deskrizzjoni tal-pakkett:

Tagħrif addizzjonali

Entitlement type:
Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
  • Elanco GmbH
Marketing authorisation date:
Siti ta’ manifattura b’rilaxx tal-lott:
  • Elanco France S.A.S
Awtorità responsabbli:
  • European Commission
Numru tal-awtorizzazzjoni:
Din l-informazzjoni mhijiex disponibbli għal dan il-prodott.
Data tal-bidla fl-istatus tal-awtorizzazzjoni:

Dokumenti

Combined File of all Documents

Malti (PDF)
Ippubblikat fuq: 11/01/2024
Niżżel
Bulgarian (PDF)
Ippubblikat fuq: 11/01/2024
Croatian (PDF)
Ippubblikat fuq: 11/01/2024
Czech (PDF)
Ippubblikat fuq: 11/01/2024
Danish (PDF)
Ippubblikat fuq: 11/01/2024
Dutch (PDF)
Ippubblikat fuq: 11/01/2024
English (PDF)
Ippubblikat fuq: 11/01/2024
Estonian (PDF)
Ippubblikat fuq: 11/01/2024
Finnish (PDF)
Ippubblikat fuq: 11/01/2024
French (PDF)
Ippubblikat fuq: 11/01/2024
German (PDF)
Ippubblikat fuq: 11/01/2024
Greek (PDF)
Ippubblikat fuq: 11/01/2024
Hungarian (PDF)
Ippubblikat fuq: 11/01/2024
Icelandic (PDF)
Ippubblikat fuq: 11/01/2024
Italian (PDF)
Ippubblikat fuq: 11/01/2024
Latvian (PDF)
Ippubblikat fuq: 11/01/2024
Lithuanian (PDF)
Ippubblikat fuq: 11/01/2024
Norwegian (PDF)
Ippubblikat fuq: 11/01/2024
Polish (PDF)
Ippubblikat fuq: 11/01/2024
Portuguese (PDF)
Ippubblikat fuq: 11/01/2024
Romanian (PDF)
Ippubblikat fuq: 11/01/2024
Slovak (PDF)
Ippubblikat fuq: 11/01/2024
Slovenian (PDF)
Ippubblikat fuq: 11/01/2024
Spanish (PDF)
Ippubblikat fuq: 11/01/2024
Swedish (PDF)
Ippubblikat fuq: 11/01/2024

ema-puar-galliprant-v-4222-par-en.pdf

English (PDF)
Ippubblikat fuq: 14/03/2023
Niżżel
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."